Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): N. Martínez-Lago, M. Reboredo López, M.C. Riesco Martínez, S. López Peraita, B. González Gómez, C. Antonilli Pérez, I. Ghanem, M. Pérez Martelo, A. López Alfonso, A. Fernández Montes, S. Agraso Busto, A.M. Jiménez Gordo, M. Melian Sosa, E. Gallardo Martín, L. Cabezón-Gutiérrez, A. Cousillas Castiñeiras, M. LLanos Muñoz, M.P. Ochoa Rivas, D. Gutiérrez Abad, J. de la Cámara Gómez
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2949819826001044?dgcid=rss_sd_all
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S2949819826001044?dgcid=rss_sd_all
“Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain.” ESMO Gastrointestinal Oncology.
@article{article44787,
title = {Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2949819826001044?dgcid=rss_sd_all}
}